Related references
Note: Only part of the references are listed.EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial
Gerd R Burmester et al.
LANCET (2020)
Effect of daily low dose prednisone, divided or single daily dose, in the treatment of African Americans with early rheumatoid arthritis
Doyt L. Conn et al.
CLINICAL RHEUMATOLOGY (2018)
Effectiveness of methotrexate with step-down glucocorticoid remission induction ( COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1-year results of CareRA, a randomised pragmatic open-label superiority trial
Patrick Verschueren et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Official View on Glucocorticoids in Rheumatoid Arthritis: A Systematic Review of International Guidelines and Consensus Statements
Yannick Palmowski et al.
ARTHRITIS CARE & RESEARCH (2017)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force
Cindy Strehl et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Can adverse effects of glucocorticoid therapy be prevented and treated?
M. C. van der Goes et al.
EXPERT OPINION ON PHARMACOTHERAPY (2016)
Glucocorticoids and chronic inflammation
Rainer H. Straub et al.
RHEUMATOLOGY (2016)
Is the Availability of Delayed-Release Prednisone an Important Clinical Advance?
Doyt L. Conn
ARTHRITIS CARE & RESEARCH (2016)
A non-inferiority trial of an attenuated combination strategy ('COBRA-light') compared to the original COBRA strategy: clinical results after 26 weeks
Debby den Uyl et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2)
Frank Buttgereit et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Delayed-release prednisone - a new approach to an old therapy
Frank Buttgereit et al.
EXPERT OPINION ON PHARMACOTHERAPY (2013)
Decline of Mean Initial Prednisone Dosage From 10.3 to 3.6 mg/day to Treat Rheumatoid Arthritis Between 1980 and 2004 in One Clinical Setting, With Long-Term Effectiveness of Dosages Less Than 5 mg/day
Theodore Pincus et al.
ARTHRITIS CARE & RESEARCH (2013)
Low-Dose Prednisone Inclusion in a Methotrexate-Based, Tight Control Strategy for Early Rheumatoid Arthritis A Randomized Trial
Marije F. Bakker et al.
ANNALS OF INTERNAL MEDICINE (2012)
Comparative Overview of Safety of the Biologics in Rheumatoid Arthritis
Majed Khraishi
JOURNAL OF RHEUMATOLOGY (2009)
Comparison of treatment strategies in early rheumatoid arthritis - A randomized trial
Yvonne P. M. Goekoop-Ruiterman et al.
ANNALS OF INTERNAL MEDICINE (2007)
Circadian rhythms in rheumatoid arthritis - Implications for pathophysiology and therapeutic management
Rainer H. Straub et al.
ARTHRITIS AND RHEUMATISM (2007)
Do steroids increase lymphoma risk?: A case-control study of lymphoma risk in polymyalgia rheumatica/giant cell arteritis
J Askling et al.
ANNALS OF THE RHEUMATIC DISEASES (2005)
Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years - A multicenter, double-blind, placebo-controlled trial
S Wassenberg et al.
ARTHRITIS AND RHEUMATISM (2005)
Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate -: A two-year randomized trial
B Svensson et al.
ARTHRITIS AND RHEUMATISM (2005)
Cost-effectiveness of low dose corticosteroids versus non-steroidal anti-inflammatory drugs and COX-2 specific inhibitors in the long-term treatment of rheumatoid arthritis
SC Bae et al.
RHEUMATOLOGY (2003)
Inadequately low serum levels of steroid hormones in relation to interleukin-6 and tumor necrosis factor in untreated patients with early rheumatoid arthritis and reactive arthritis
RH Straub et al.
ARTHRITIS AND RHEUMATISM (2002)
Industry and academy: The synthesis of steroids
LB Slater
HISTORICAL STUDIES IN THE PHYSICAL AND BIOLOGICAL SCIENCES (2000)
Share Paper
